# Bevacizumab-Bvzr (Zirabev)

Source: https://ourhealthnetwork.com/drugs/bevacizumab-bvzr
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Bevacizumab-Bvzr?

Bevacizumab-Bvzr (brand name: Zirabev) is a vascular endothelial growth factor inhibitor. It is prescribed to treat uterine cervical neoplasms, colorectal neoplasms, fallopian tube neoplasms. Across the United States, 47 doctors prescribe Bevacizumab-Bvzr to approximately 38 Medicare patients.

## Brand names

Zirabev

## Indications

Bevacizumab-Bvzr is prescribed for several conditions including uterine cervical neoplasms, colorectal neoplasms, fallopian tube neoplasms, among others.

## Conditions treated

- [Uterine Cervical Neoplasms](https://ourhealthnetwork.com/conditions/uterine-cervical-neoplasms)
- [Colorectal Neoplasms](https://ourhealthnetwork.com/conditions/colorectal-neoplasms)
- [Fallopian Tube Neoplasms](https://ourhealthnetwork.com/conditions/fallopian-tube-neoplasms)
- [Glioblastoma](https://ourhealthnetwork.com/conditions/glioblastoma)
- [Carcinoma](https://ourhealthnetwork.com/conditions/carcinoma)
- [Non-Small-Cell Lung](https://ourhealthnetwork.com/conditions/non-small-cell-lung)
- [Ovarian Neoplasms](https://ourhealthnetwork.com/conditions/ovarian-neoplasms)
- [Peritoneal Neoplasms](https://ourhealthnetwork.com/conditions/peritoneal-neoplasms)
- [Kidney Neoplasms](https://ourhealthnetwork.com/conditions/kidney-neoplasms)

## Mechanism of action

Bevacizumab products bind VEGF and prevent the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis.

## Drug classification

- Established Pharmacologic Class: Vascular Endothelial Growth Factor Inhibitor [EPC]
- Mechanism of Action class: Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
- Route of administration: INTRAVENOUS

## Common side effects

headache, rhinitis

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)